Amicus Therapeutics (FOLD) Scheduled to Post Quarterly Earnings on Monday

Amicus Therapeutics (NASDAQ:FOLD) is scheduled to issue its quarterly earnings data before the market opens on Monday, November 5th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.33). The firm had revenue of $21.31 million during the quarter, compared to the consensus estimate of $18.92 million. Amicus Therapeutics had a negative return on equity of 53.45% and a negative net margin of 460.04%. On average, analysts expect Amicus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ FOLD opened at $11.85 on Friday. The company has a current ratio of 10.88, a quick ratio of 10.73 and a debt-to-equity ratio of 0.30. Amicus Therapeutics has a 12 month low of $10.33 and a 12 month high of $17.62.

FOLD has been the subject of several research analyst reports. ValuEngine downgraded Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 19th. Zacks Investment Research raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Tuesday, July 10th. Cowen reissued a “buy” rating and set a $31.00 target price on shares of Amicus Therapeutics in a research note on Friday, October 12th. Chardan Capital reissued a “hold” rating and set a $15.00 target price on shares of Amicus Therapeutics in a research note on Friday, October 12th. Finally, Citigroup assumed coverage on Amicus Therapeutics in a report on Monday, October 29th. They set a “neutral” rating and a $12.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $19.50.

In other news, major shareholder Perceptive Advisors Llc purchased 20,000 shares of Amicus Therapeutics stock in a transaction dated Monday, September 24th. The shares were bought at an average cost of $12.45 per share, for a total transaction of $249,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO William D. Baird III sold 10,000 shares of the business’s stock in a transaction dated Monday, October 15th. The stock was sold at an average price of $12.23, for a total value of $122,300.00. Following the sale, the chief financial officer now owns 127,622 shares in the company, valued at $1,560,817.06. The disclosure for this sale can be found here. Over the last 90 days, insiders have bought 620,000 shares of company stock worth $7,505,000. Company insiders own 2.90% of the company’s stock.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Featured Story: What are retained earnings?

Earnings History for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply